Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain.

Crosignani PG, Luciano A, Ray A, Bergqvist A

Human reproduction (Oxford, England)21 Sept 2005Cited by 108 (Europe PMC)

PMID16176939DOI10.1093/humrep/dei290PepBankPUB-16176939

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, leuprolide and DMPA produced equivalent reductions in at least four pain categories at months 6 and 18.
In plain wordsIn women with endometriosis, leuprolide and DMPA produced equivalent pain reductions at months 6 and 18.
Peptide
Leuprolide
Outcome
No significant changePain categories
Study
n: not reported in source
Comparator
DMPA-SC 104
Outcome group
Pain · Reproductive and sexual health
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · 6 monthsAs given in this study (human).
Measurements
P
< 0.02
equivalence of reductions in at least four pain categories
Source sentences
Summary
DMPA-SC 104 and leuprolide produced equivalent (P < 0.02) reductions in at least four pain categories and significant (P < 0.001) improvements in composite score at months 6 and 18.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months)
Report a problemFND-1617693901
02HumanRandomized controlled trialSafety outcome
In women with endometriosis, total hip BMD reduction at month 6 was greater with leuprolide than DMPA.
In plain wordsIn women with endometriosis, hip bone density loss at month 6 was greater with leuprolide than DMPA.
Peptide
Leuprolide
Outcome
IncreaseTotal hip BMD reduction
Study
n: not reported in source
Comparator
DMPA-SC 104
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · 6 monthsAs given in this study (human).
Measurements
P
< 0.001
total hip BMD, month 6, DMPA-SC 104 versus leuprolide
Source sentences
Summary
At month 6, reductions in total hip and lumbar spine BMD were significantly less (P < 0.001) with DMPA-SC 104 versus leuprolide.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months)
Report a problemFND-1617693903
03HumanRandomized controlled trialSafety outcome
In women with endometriosis, lumbar spine BMD reduction at month 6 was greater with leuprolide than DMPA.
In plain wordsIn women with endometriosis, spine bone density loss at month 6 was greater with leuprolide than DMPA.
Peptide
Leuprolide
Outcome
IncreaseLumbar spine BMD reduction
Study
n: not reported in source
Comparator
DMPA-SC 104
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · 6 monthsAs given in this study (human).
Measurements
P
< 0.001
lumbar spine BMD, month 6, DMPA-SC 104 versus leuprolide
Source sentences
Summary
At month 6, reductions in total hip and lumbar spine BMD were significantly less (P < 0.001) with DMPA-SC 104 versus leuprolide.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months)
Report a problemFND-1617693904
04HumanRandomized controlled trialSafety outcome
In women with endometriosis, BMD did not return to pretreatment levels after leuprolide, unlike DMPA, 12 months after treatment.
In plain wordsIn women with endometriosis, bone density did not return to pretreatment levels after leuprolide, unlike DMPA.
Peptide
Leuprolide
Outcome
DecreaseBMD recovery
Study
n: not reported in source
Comparator
DMPA-SC 104
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · 6 monthsAs given in this study (human).
Source sentences
Summary
BMD returned to pre-treatment levels 12 months post-treatment in the DMPA-SC 104 but not the leuprolide group.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months)
Report a problemFND-1617693905
05HumanNon-randomized trialEfficacy outcome
In women with endometriosis, composite scores improved significantly at months 6 and 18 in both the leuprolide and DMPA groups.
In plain wordsIn women with endometriosis, composite scores improved at months 6 and 18 in both the leuprolide and DMPA groups.
Peptide
Leuprolide
Outcome
Direction not reportedComposite symptom score
Study
n: not reported in source
Outcome group
Pain · Reproductive and sexual health
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · 6 monthsAs given in this study (human).
Measurements
P
< 0.001
composite score improvement
Source sentences
Summary
DMPA-SC 104 and leuprolide produced equivalent (P < 0.02) reductions in at least four pain categories and significant (P < 0.001) improvements in composite score at months 6 and 18.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months)
Report a problemFND-1617693902
06HumanNon-randomized trialEfficacy outcome
In women with endometriosis, total productivity significantly improved at months 6 and 18 in both the leuprolide and DMPA groups.
In plain wordsIn women with endometriosis, productivity improved at months 6 and 18 in both the leuprolide and DMPA groups.
Peptide
Leuprolide
Outcome
IncreaseTotal productivity
Study
n: not reported in source
Outcome group
Exercise and physical function · Reproductive and sexual health
Studied dose
3.75 mg monthly or 11.25 mg every 3 months · 6 monthsAs given in this study (human).
Measurements
P
≤ 0.05
total productivity, both groups
Source sentences
Summary
Total productivity also significantly (P < or = 0.05) improved in both groups at 6 and 18 months.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months)
Report a problemFND-1617693906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.